F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comVimta Labs Ltd is one of India’s leading contract research and testing service providers in the fields of pharmaceuticals, food, environment, clinical diagnostics, and more. With over three decades of experience and a reputation for quality testing and compliance, Vimta Labs has established itself as a reliable name in the health science sector.
In this article, we will explore the current status of Vimta Labs stock and forecast its share price targets from 2025 to 2030.
| Detail | Value |
|---|---|
| Current Price (Open) | ₹512.55 |
| Previous Close | ₹505.95 |
| Day's High | ₹579.45 |
| Day's Low | ₹500.25 |
| 52-Week High | ₹589.00 |
| 52-Week Low | ₹242.05 |
| Market Cap | ₹2,558 Cr |
| Beta (Volatility) | 0.90 |
| Volume | 1.11 Cr |
| VWAP | ₹566.92 |
| Book Value Per Share | ₹85.12 |
| Dividend Yield | 0.35% |
| Face Value | ₹2 |
Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad. The company provides a wide range of contract research and testing services across pharma, biotech, and clinical research industries. Its services include:
Drug discovery and development support
Food and environmental testing
Clinical reference diagnostics
Bioanalytical services
Pre-clinical and clinical trial support
With a diversified portfolio and growing demand for regulatory-compliant testing, Vimta Labs continues to expand its client base in India and globally.
Strong Research Capabilities: Trusted by top pharmaceutical companies for regulatory-compliant research and testing.
Diversified Revenue Streams: Revenue from pharma, diagnostics, food safety, and environmental services.
Expansion Plans: Ongoing investment in infrastructure and lab automation to scale capacity.
Stable Financials: Improving profit margins and consistent revenue growth.
Beta of 0.90: Indicates lower volatility compared to broader market indices.
| Shareholder Category | Holding (%) |
|---|---|
| Retail and Others | 58.42% |
| Promoters | 36.67% |
| Foreign Institutions | 3.49% |
| Other Domestic Institutions | 1.42% |
Retail investors dominate the shareholding structure, showing wide public trust and interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | ₹530 | ₹580 |
| 2026 | ₹595 | ₹650 |
| 2027 | ₹660 | ₹720 |
| 2028 | ₹735 | ₹810 |
| 2029 | ₹820 | ₹895 |
| 2030 | ₹910 | ₹990 |
These forecasts are based on the company’s fundamentals, industry outlook, earnings growth, and technical trends.
Vimta Labs is expected to remain on a growth trajectory in 2025 due to a rise in demand for clinical diagnostics and pharma testing.
Why?
Growing health awareness post-pandemic
Government push for food and drug safety
Increase in domestic and global pharma exports
Investment Advice: Suitable for medium-risk investors with a 3-year view. Consider buying on dips.
In 2026, the company is expected to benefit from lab expansions and automation investments.
Why?
Revenue growth from global clients
Efficiency gains from tech integration
Rising share in the diagnostic market
Investment Advice: Hold for further upside; monitor earnings growth and institutional interest.
By 2027, Vimta Labs could see benefits from increased outsourcing in pharma and biotech research.
Why?
Expansion into newer geographies
Diversified service offerings
Clinical trial and CRO market growth
Investment Advice: Reinvest dividends and stay invested for compounding returns.
Continued momentum is likely in 2028 due to regulatory approvals and high-quality infrastructure.
Why?
Demand from food safety & diagnostics
Strong balance sheet & minimal debt
Strategic tie-ups with global pharma
Investment Advice: Keep SIPs active and add during market corrections.
By 2029, Vimta could become a top midcap pharma services company in India.
Why?
Consistent growth in net profit
Improved ROE and ROCE metrics
Potential for international acquisitions
Investment Advice: Ideal for long-term capital appreciation with balanced risk.
In 2030, Vimta Labs may hit new highs supported by strong fundamentals and sectoral tailwinds.
Why?
Dominant position in contract research
Long-term contracts with global pharma
Continuous innovation and skilled workforce
Investment Advice: Long-term investors may benefit greatly from holding; good for goal-based planning (retirement, children’s education, etc.)
Yes. Vimta Labs has shown consistent growth in revenues, low debt, and increasing relevance in the regulated testing space, making it an attractive long-term investment.
Niche and growing industry (pharma & diagnostics)
Healthy financial performance
Low beta = low risk
Strong promoter backing
Regular dividend payout
Regulatory delays and compliance costs
Dependence on pharma and export orders
Price sensitivity due to investor concentration
Competition from global CROs
Vimta Labs Ltd has emerged as a strong mid-cap player in the pharma and diagnostics testing sector. With increasing demand for testing and clinical services, the company is poised for steady growth. The share price target of ₹990 by 2030 reflects its strong fundamentals, operational excellence, and sectoral tailwinds.
If you’re looking for a fundamentally strong healthcare-related stock with decent returns and low volatility, Vimta Labs could be a solid addition to your long-term portfolio.
1. What is the next target of Vimta Labs share?
In 2025, the short-term target is between ₹530 and ₹580.
2. Is Vimta Labs a good stock to buy?
Yes, for long-term investors seeking healthcare exposure with low risk.
3. What is the current market cap of Vimta Labs?
As of July 2025, the market cap is approximately ₹2,558 Cr.
4. What is the all-time high price of Vimta Labs?
The all-time high is ₹589.00.
5. What is the face value of Vimta Labs shares?
₹2 per share.
6. Who are the major shareholders of Vimta Labs?
Promoters hold 36.67%, and retail investors hold 58.42%.
7. What is the dividend yield of Vimta Labs?
Currently, 0.35%.
8. What is Vimta Labs known for?
It is known for contract research and diagnostic services in pharma and life sciences.
9. What is the risk level of investing in Vimta Labs?
Moderate to low risk due to stable industry and low beta (0.90).
10. How much has the stock grown from its 52-week low?
From ₹242.05 to ₹505.95 — more than 100% gain.
Disclaimer: This blog is for educational and informational purposes only. Please consult a certified financial advisor before making any investment decisions.
Register & Login